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Cd36 knockout mice are protected against lithogenic
diet-induced gallstones
Yan Xie,* Vincenza Cifarelli,† Terri Pietka,† Elizabeth P. Newberry,* Susan M. Kennedy,*
Amin Khalifeh-Soltani,§ Robin Clugston,** Kamran Atabai,§ Nada A. Abumrad,1,2,†
and Nicholas O. Davidson1,2,*
Gastroenterology Division,* Center for Human Nutrition,† Department of Medicine, Washington University
School of Medicine, St. Louis, MO; Cardiovascular Research Institute,§ Department of Medicine, University
of California, San Francisco, CA; and Department of Physiology,** University of Alberta, Edmonton, Canada

Abstract The scavenger receptor and multiligand transporter
CD36 functions to promote cellular free fatty acid uptake and
regulates aspects of both hepatic and intestinal cholesterol metabolism. However, the role of CD36 in regulating canalicular
and biliary cholesterol transport and secretion is unknown.
Here, we show that germline Cd36 knockout (KO) mice are
protected against lithogenic diet (LD)-induced gallstones compared with congenic (C57BL6/J) controls. Cd36 KO mice
crossed into congenic L-Fabp KO mice (DKO mice) demonstrated protection against LD-induced gallstones, reversing the
susceptibility phenotype observed in L-Fabp KO mice. DKO
mice demonstrated reduced biliary cholesterol secretion and
a shift into more hydrophophilic bile acid species, without
changes in either BA pool size or fecal excretion. In addition,
we found that the mean and maximum force of gallbladder
contraction was increased in germline Cd36 KO mice, and gallbladder lipid content was reduced compared with wild-type
controls. Finally, whereas germline Cd36 KO mice were protected against LD-induced gallstones, neither liver- nor
intestine-specific Cd36 KO mice were protected. Taken
together, our findings show that CD36 plays an important
role in modifying gallstone susceptibility in mice, at least
in part by altering biliary lipid composition, but also by
promoting gallbladder contractility.—Xie, Y., V. Cifarelli,
T. Pietka, E. P. Newberry, S. Kennedy, A. Khalifeh-Soltani,
R. Clugston, K. Atabai, N. A. Abumrad, and N. O. Davidson.
Cd36 knockout mice are protected against lithogenic dietinduced gallstones. J. Lipid Res. 2017. 58: 1692–1701.
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Gallstone disease and its comorbidities continue to represent a healthcare and economic challenge in the developed world (1). Our understanding of the pathogenesis of
cholesterol gallstone disease includes both genetic and environmental risk factors, events that converge on pathways
that regulate hepatic cholesterol metabolism and canalicular lipid secretion (2, 3). Genome-wide association studies
implicate susceptibility loci with functions in cholesterol
metabolism and transport, in particular the canalicular
cholesterol transporter ABCG5/G8 (4, 5). Other studies,
using inbred mouse strains, have led to the identification
of quantitative trait loci and corresponding positional
candidate genes that predispose to lithogenic diet (LD)induced gallstones (6, 7).
Studies examining environmental and genetic risk factors suggest that several distinct metabolic pathways modify gallstone susceptibility. These pathways include those
regulated by nuclear hormone receptors involved in sterol
and bile acid sensing (8, 9), as well as pathways more
broadly involved in hepatic lipid utilization and metabolic
channeling. For example, mice with germline deletion of
L-Fabp, while protected against diet-induced hepatic steatosis
(10, 11) demonstrated increased LD-induced gallstone formation, at least in part through augmented canalicular cholesterol secretion (12). Similarly, germline deletion of Elovl6
attenuated hepatic steatosis in Ldlr KO mice, yet enhanced
gallstone susceptibility (13). Here, we asked whether the
multiligand class B scavenger receptor CD36 might play a
role in modifying hepatic cholesterol utilization and export. This possibility was in part predicated on findings that
mouse hepatic CD36 expression is increased in response to

Abbreviations: bw, body weight; CCK, cholecystokinin; Cd36-IKO,
intestine-specific Cd36 KO; Cd36-LKO, liver-specific Cd36 KO; ChMC,
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lithogenic diet.
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MATERIALS AND METHODS
Animals and diets
All animals were maintained in a C57BL6/J background and
housed on a 12 h light-dark cycle, in a full-barrier facility. Ten- to
12-week-old male mice were fed either standard rodent chow
(PicoLab Rodent Diet 20, fat 4.5%, cholesterol 0.015%) or an LD
(Research Diet no. 960393, fat 18.8%, cholesterol 1.2%, and cholic
acid 0.5%) for 2–4 weeks, as indicated. L-Fabp/ mice (12) and
Cd36/ mice (21) were used in crosses to generate a line of compound Cd36, L-Fabp double KO mice (hereafter referred to as
DKO). Cd36 conditional KO mice were generated from Cd36flox/flox
mice (22) crossed into either Albumin-Cre or Villin-Cre lines (Jax)
to generate the compound line of tissue-specific KO (either liveror intestine-specific) mice. Age-matched and cohoused littermates
were used as controls. All animal protocols were approved by the
Washington University Animal Studies Committee and followed
guidelines outlined by the National Institutes of Health.

Tissue and serum lipid determinations
Animals were euthanized after a 4 h fast. Liver and serum were
collected and frozen at 80°C until analyzed. Serum triglyceride
and cholesterol were measured by using reagents from Wako
(Neuss, Germany), an L-Type Triglyceride M Kit (catalog nos.
465-09791 and 461-09891), and the cholesterol E kit (catalog no.
439-17501). Hepatic or, where indicated, gallbladder lipids were
extracted by using chloroform: methanol (2:1) and triglyceride,
cholesterol, free cholesterol, free fatty acids, and phospholipids
enzymatically with the indicated Wako reagent kits: the L-Type
Triglyceride M Kit, the cholesterol E kit, the free cholesterol E kit
(catalog no. 435-35801), the HR series NRFA-HR2 kit (catalog nos.
991-34891 and 995-34791), and the phospholipid C kit (catalog no.
433-36201).

Gallstone analysis and gallbladder bile cholesterol
saturation index
Animals were fed a LD for 4 weeks as indicated in the relevant
figure legends and euthanized after a 4 h fast. Fresh gallbladder
bile was immediately analyzed by polarizing microscopy using a
visual scale with the following criteria: 0, absence of cholesterol
monohydrate crystals (ChMCs), 1, small number of ChMCs (<3 per
high power field); 2, many ChMCs (3 per high power field);

3 = aggregated ChMCs; and 4 = presence of “sandy” light-translucent
stones or “solid” light-opaque stones (7). Gallbladder bile cholesterol content was measured enzymatically after chloroform:
methanol (2:1) extraction. Gallbladder bile phospholipids and
bile acid content were analyzed enzymatically by using the total
bile acids assay kit (BQ 092A-EALD, BQ Kits, San Diego, CA).
Cholesterol saturation indices in gallbladder bile were calculated
by using published parameters (23).

Biliary lipid secretion and bile acid pool size
Mice were fed a LD for 2 weeks and anesthetized after a 4 h fast.
An external bile fistula was established surgically, and bile samples
collected during the first 15 min were discarded. Bile samples were
collected for another 60 min and used for biliary lipid secretion
analysis. Hepatic bile volume was determined gravimetrically assuming a density of 1 g·ml1. Biliary phospholipids, cholesterol, and total bile acid content were determined enzymatically. Biliary lipid
secretion values are presented as nmol/min/kg body weight (bw).
Individual bile acid species were determined by using HPLC as previously described (12) and with commercially obtained standards.
The hydrophobicity index was calculated by using published parameters (24). Bile acid pool size and fecal bile acids excretion were determined in groups of mice fed a LD for 2 weeks. For bile acid pool
size, the liver, gallbladder, and intestine were homogenized together, and bile acid content was measured as previously detailed
(12). For fecal bile acid excretion, feces from individual animals
were collected for up to 72 h. Feces were homogenized, and bile
acid content was determined enzymatically.

Gene expression analysis
Hepatic total RNA or proximal intestinal RNA was extracted
and cDNA was prepared by using an ABI high-capacity cDNA reverse transcription kit with 1 µg of total RNA. Real-time quantitative PCR used cDNAs from four to six animals per group and was
performed in triplicate on an ABI Prism7000 sequence detection
system using SYBR Green PCR Master Mix (Applied Biosystems)
and primer pairs (provided on request) designed by Primer Express software (Applied Biosystems). Relative mRNA abundance is
expressed as fold change to WT control after normalization to own
GAPDH. To detect hepatic CD36 and L-Fabp protein, 50 mg of
liver was homogenized in 0.5 ml of buffer containing 25 mM
HEPES, 150 mM NaCL, 0.5 mM EDTA, 0.1% SDS, 1% Triton, and
protease inhibitors, by using the Bullet BlenderR system (Next Advance) with 1 mm zirconium oxide beads. Aliquots of 50 µg of
protein were separated by 4–20% SDS-PAGE gel. Samples of terminal ileum protein were used to prepare total and membrane extracts as described (12, 25) by using the Bullet BlenderR system
with 1 mm steel beads. In brief, approximately 50–100 mg of fullthickness ileum was homogenized in 0.8 ml of lysis buffer (250 mM
sucrose and 10 mM Triethanolamine-HCL, pH 7.6) containing
protease inhibitors (Complete protease inhibitor mixture, Roche
Diagnostics). The crude preparation was centrifuged at 2,500 g for
10 min, and the supernatant was recentrifuged at 30,000 g for
60 min at 4°C by using a Beckman MLA-130 rotor. The resulting
membrane pellet was resuspended in solubilization buffer [15%
SDS, 8 M Urea, 10% (w/v) sucrose, 62.5 mM Tris-HCL, and 5 mM
dithiothreitol, pH 6.8]. Membrane proteins (50 µg) were separated on 10% SDS-PAGE gel, transferred to Immobilon®-P membranes (Millipore, Billerica, MA), and immunoblotted with 1:2,000
goat anti-mouse CD36 (16), 1:2,000 rabbit anti-mouse L-Fabp
(26), 1:300 rabbit anti-mouse Fgf15, and 1:1,000 monoclonal rabbit anti-mouse Asbt antibody (generous gifts from Dr. Paul A Dawson), and quantitated by Kodak Image software.
Gallbladder contractility studies. Gallbladders were taken
/
from age- and sex-matched (male) chow-fed WT and Cd36
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high-fat diet-induced obesity and other findings that adenoviral-mediated hepatic CD36 overexpression increased
hepatic FFA uptake and steatosis (14). In addition, CD36
has been shown to regulate cholesterol uptake, utilization,
and secretion from both the small intestine (15, 16) and
mouse peritoneal macrophages (17).
Beyond the metabolic alterations alluded to above, there
is a role for altered gallbladder motility in promoting gallstone susceptibility, evidenced by findings in both Cck KO
mice and in Cckr1 KO mice (18, 19). These findings, coupled with findings that CD36-dependent signaling promotes secretin and cholecystokinin (CCK) release from
enteroendocrine cells (20), raised the question of whether
CD36 might function more broadly in modifying gallstone
susceptibility, specifically via alterations in gallbladder contractility. Here, we show that germline Cd36 KO mice are
protected against LD-induced gallstones via mechanisms
including alterations in biliary cholesterol secretion, bile
acid composition, and enhanced gallbladder contractility.

mice. Both surfaces of the excised gallbladder were gently cut and
washed with PBS and attached to a force transducer (Radnoti
8-chamber tissue-organ bath system) exactly as described (27).
Gallbladders were immersed in warmed, oxygenated buffer for
30 min before the addition of the indicated concentrations of
methacholine and KCl. Resting tension of 0.5 g was applied after
each treatment as previously described (28).

Statistical analysis
Statistical significance was determined with one-way ANOVA
for multiple group comparisons and t-testing as a post hoc test
for comparing different pairs using GraphPad Prism 7 software
(GraphPad, San Diego, CA). Data are expressed as the mean ± SE
unless otherwise noted.

RESULTS

Fig. 1. Cd36/ mice are protected against gallstones, and Cd36
deletion confers protection in L-Fabp/ mice (DKO mice) after 4
weeks of LD feeding. A: Hepatic CD36 and L-Fabp protein expression were determined by Western blotting of total liver extracts.
CD36 protein was not detected in either Cd36/ mice or DKO
liver, and L-Fabp protein was likewise not detected in either
L-Fabp/ or DKO liver as predicted. B: Representative gross appearances of gallbladder after 4 weeks of LD feeding. Gallbladders
from WT and L-Fabp/ mice appear opaque with visible solid
stones, whereas gallbladders from Cd36/ mice and DKO are
transparent without visible stones. Gallstone incidence (C) and gallstone score (D) were significantly reduced in both Cd36/ mice
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Gallstone protection in Cd36/ mice is associated with
alterations in biliary lipid secretion
Hepatic lipid content across the genotypes in LD-fed
mice indicated no major differences in total or free cholesterol content, but revealed increased bile acid content in
/
and DKO mice (Table 1). We next examined
both Cd36
the concentration and relative distribution of the most
abundant individual bile acid species from newly secreted
bile samples in each genotype. These data revealed increased biliary concentration of taurobetamuricholic acid
in LD-fed Cd36/ mice (Fig. 2A) with a shift in relative

and in DKO mice. E: Gallbladder volume was determined gravimetrically (Materials and Methods). F: Cholesterol saturation index
(CSI) of gallbladder bile was calculated as described in Materials
and Methods. Cd36/ and DKO mice demonstrate a similar decrease in CSI compared with WT and L-Fabp/ mice, n = 6–12
mice per group. The data associated with different superscript
letters are significantly different (P < 0.05). The data reflect the
mean ± SE. *Statistically significant differences (P < 0.05).

Downloaded from www.jlr.org at Washington Univ Medical Library, on August 29, 2017

Cd36 deletion protects against LD-induced gallstones and
attenuates gallstone susceptibility in L-Fabp KO mice
Our first objective was to ascertain a role for CD36 in LDinduced gallstone susceptibility. Mice of the indicated geno
type (Fig. 1A) were studied after consuming a LD for 4
/
mice (Fig. 1A)
weeks, with the data showing that Cd36
exhibited a striking reduction in gallstone incidence with
correspondingly reduced gallstone score and reduced cholesterol saturation index (Fig. 1B). Furthermore, when
crossed into germline L-Fabp/ mice, both Cd36/and
the compound DKO mice (Fig. 1A, B) were protected, as
evidenced by the visually clear appearance of the gallbladder, decreased cholesterol saturation index, and reduced
gallbladder volume (Fig. 1B). We observed increased abundance of L-Fabp protein in livers from LD-fed Cd36 KO
mice compared with WT controls (Fig. 1A), an observation
whose underlying mechanisms remain to be elucidated.
However, these findings point to a role of CD36 as a modifier of murine gallstone susceptibility in mice either WT or
null for the L-Fabp allele.

TABLE 1. Hepatic lipid content in LD-fed mice of the indicated genotype
Genotype

WT (6)
Cd36/ (6)
L-Fabp/ (5)
DKO (6)

TC

159.8 ± 22.9
159.8 ± 10.4
147.5 ± 11.6
159.4 ± 24.9

FC

27.5 ± 1.3
31.0 ± 4.8
24.0 ± 3.7
32.4 ± 1.9

CE

PL

132.3 ± 22.9
128.8 ± 10.9
123.6 ± 12.3
127.0 ± 26.7

85.6 ± 2.4
92.5 ± 5.0
95.8 ± 4.6
93.9 ± 2.7

FFA

BA
a

86.6 ± 5.6
a
85.0 ± 4.9
a
80.7 ± 9.1
132.9 ± 10.9b

21.8 ± 9.1a
27.1 ± 15.1a
19.6 ± 4.1a
33.2 ± 11.2a

Mice from four experimental groups (n per group) were fed a LD for 4 weeks. Hepatic lipids were extracted and
analyzed (Materials and Methods). Hepatic lipid content is expressed as mean ± SE (µg/mg protein), except FFA
(nmol/mg protein). The difference between values associated with different superscript letters for the parameters
indicated in each vertical column is statistically significant (P < 0.05). BA, bile acid; CE, cholesteryl ester; FC, free
cholesterol; FFA, free fatty acid; PL, phospholipid; TC, total cholesterol.

/

mice is associated with
Gallstone protection in Cd36
alterations in genes regulating hepatic and intestinal
cholesterol and bile acid metabolism
We next sought to understand the mechanisms underlying the alterations in biliary lipid secretion noted above by
profiling the expression of several mRNAs involved in hepatic cholesterol and bile acid homeostasis. We observed
/
mice
decreased expression of hepatic Cyp7a1 in L-Fabp
as previously demonstrated (12) and also in both genotypes of Cd36/ mice, which was accompanied by increased Cyp8b1 expression in LD-fed Cd36/ and DKO
mice (Fig. 3A). The increased expression of hepatic Cyp8b1
mRNA in Cd36/ and DKO mice was not accompanied by
increased biliary taurocholate concentration, as might be
predicted (29, 30), but it bears emphasis that those bile
acid distribution data (Fig. 2A and above) reflect mice fed
supplemental cholic acid as part of the LD regimen. We
also observed decreased expression of HMGR mRNA in
Cd36/ and DKO mice, findings suggesting that de novo
hepatic cholesterol production may be decreased, a possibility consistent with the decreased secretion of biliary

cholesterol noted above, as well as earlier findings suggest/
mice (31).
ing decreased de novo lipogenesis in Cd36
We next turned to an examination of a panel of intestinal genes involved in cholesterol and bile acid metabolism, in part guided by previous findings of regionally
specific adaptive alterations in their expression in germline Cd36/ mice (16). Our findings revealed decreased
expression of NPC1L1 mRNA and protein in both Cd36/
and DKO mice (Fig. 3B, C) and increased expression of
SRB1 in proximal intestinal samples (Fig. 3B, C) along
with decreased mRNA abundance of ABCG5/G8 in germline Cd36/ mice (Fig. 3B). These findings point to the
possibility of altered intestinal cholesterol uptake and absorption in LD-fed Cd36/ and DKO mice, consistent with
prior findings showing decreased cholesterol absorption
in chow-fed Cd36/ mice (15, 16). We observed increased
ileal expression of FGF15 expression in L-Fabp/ mice, but
no change in ASBT expression in any genotype. Taken together, these findings suggest a range of adaptive changes
in enterohepatic cholesterol and bile acid metabolism in
LD-fed mice of the respective genotypes, raising the possibility that either intestinal- or hepatic-specific Cd36 deletion
might reveal a dominant pathway that confers protection
against gallstones.
Neither intestine- nor liver-specific Cd36 deletion protects
against LD-induced gallstone formation
We first examined intestine-specific Cd36 KO mice
(Cd36-IKO), which were generated as previously documented (22) and fed a LD for 4 weeks. We found that both
flox/flox (i.e., CD36 WT) controls and Cd36-IKO mice
demonstrated gallstones, with no differences noted in any
of the physical parameters of score or gallbladder volume
(Fig. 4A–D). In addition, there were no differences by genotype in hepatic lipid or bile acid content (Fig. 4E).
Using a similar approach, we generated liver-specific Cd36
KO mice (Cd36-LKO) using Albumin-Cre mice (Jax). We
documented liver-specific recombination at the Cd36 locus
(Fig. 5A) and knockdown of hepatocyte CD36 (Fig. 5B),
demonstrating that this strategy induced a decrease in
CD36 expression in hepatocytes at baseline in chow-fed
mice. Unexpectedly, we observed that total hepatic CD36
abundance appeared slightly increased in LD-fed Cd36LKO compared with WT controls (Fig. 5C), suggesting that
hepatocyte CD36 is likely only a minor component of overall hepatic CD36 expression. Both WT and Cd36 LKO mice
demonstrated gallstones with no difference by genotype in
CD36 deletion abrogates gallstone formation
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taurobetamuricholic acid distribution favoring enrichment in both Cd36/ and DKO mice (Fig. 2B). The net
impact of these relatively subtle, albeit significant, differences in bile acid species includes a significant decrease in
hydrophobicity index (24) in both Cd36/ and DKO mice
(Fig. 2C). Daily fecal bile acid excretion (Fig. 2D) and total
bile acid pool sizes (Fig. 2E) were comparable across the
genotypes, suggesting that there were no major shifts in enterohepatic cycling.
We further examined biliary lipid secretion rates in the
various genotypes, using a shorter (2 week) LD feeding interval. This interval was selected to circumvent the inevitable bile duct obstruction that accompanied the extensive
gallstone formation in both WT and L-Fabp/ mice noted
above. Those findings revealed increased biliary cholesterol secretion in L-Fabp/ mice compared with both WT
and Cd36/ mice (Table 2). There was a trend to decreased biliary cholesterol secretion in Cd36/ mice (175
nmol/min/kg bw) compared with WT controls (210 nmol/
min/kg bw) and in DKO mice (222 nmol/min/kg bw) compared with L-Fabp/ mice (298 nmol/min/kg bw), without changes in bile flow rate by genotype (Table 2). Taken
together, these findings suggest that altered biliary bile
acid composition and attenuated cholesterol secretion in
LD-fed Cd36/ mice may in combination contribute to the
protection observed against gallstone formation.

nor hepatocyte-specific Cd36 deletion alone can replicate
the protection against LD-induced gallstones observed in
germline Cd36/ mice.

any of the physical parameters of score or gallbladder volume and no differences by genotype in hepatic lipid or bile
acid content (Fig. 5D–H). These findings, coupled with the
data alluded to above, suggest that neither intestine-specific
1696
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DISCUSSION
The central findings of these studies are that Cd36/
mice are protected against LD-induced gallstones, through
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Fig. 2. Bile acid species, hydrophobicity, fecal bile acid excretion,
and pool size in LD-fed mice. A, B: Biliary bile was collected from
mice fed a LD for 2 weeks, and bile acid species were determined
by HPLC as described in Materials and Methods. A: Biliary bile
acid concentrations revealed an increase in taurocholate (TC)
in L-Fabp/ mice with a decrease in taurochenodeoxycholate
(TCDC) and taurodeoxycholate (TDC) concentration in Cd36/
and DKO mice compared with WT mice. B: Bile acid species distribution was altered in Cd36/ and DKO mice, with increased abundance of relatively hydrophilic bile acids tauro--muricholate
(TMC), tauroursodeoxycholate (TUDC), and glycohyodeoxycholate (GHDC) (DKO), and decreased abundance of hydrophobic
bile acids glycocholate (GC), TCDC, and glycochenodeoxycholate
(GCDC). C: Hydrophobicity index (HI) of biliary bile from representative animals of the four genotypes was calculated by using published algorithms (Materials and Methods), revealing a significant
reduction in Cd36/ and DKO mice compared with either WT or
L-Fabp/ mice. D: Fecal bile acid excretion (mol per 100 g of bw
per day) was comparable across the four genotypes. Mice were individually housed, and feces were collected for up to 72 h. Fecal bile
acids were extracted and quantitated enzymatically. E: Bile acid pool
size (mol per 100 g of bw) was comparable in four genotypes.
Liver, gallbladder, and the entire small and large intestine were
pooled and subjected to ethanolic bile acid extraction. Total bile
acid mass was measured enzymatically. The data are the mean ± SE
(n = 4–8 per group). *Statistically significant differences (P < 0.05).

Increased gallbladder contractility and reduced lipid
/
mice
accumulation in Cd36
We observed over the course of these studies that the gallbladders of Cd36/ mice appeared smaller and more contracted than their WT controls (Fig. 6A). This observation
prompted us to examine in more detail a possible role for
CD36 in gallbladder function. We confirmed that CD36
expression was undetectable in gallbladder mRNA from
Cd36/ mice (Fig. 6B) and that gallbladder CD36 mRNA
abundance was indistinguishable between WT (C57BL6/J),
Cd36 flox controls, Cd36-IKO, and Cd36-LKO mice, suggesting that neither intestine-specific (i.e., villin) nor liverspecific (i.e., albumin) Cre drivers are active in gallbladder
mucosa (Fig. 6C). Because prior work has shown a dominant role for gallbladder hypomotility in increased gallstone susceptibility (19, 32), either via decreased CCK
production or decreased CCK receptor expression (18), we
examined gallbladder contractility using in vitro preparations of gallbladders from WT and Cd36/ mice (Materials
and Methods). We observed that gallbladder contractility
was increased in response to increasing doses of KCl
and methacholine in Cd36/ mice (Fig. 6D, E) and that
both the maximum force of contraction and the rate of
smooth muscle contraction were increased in Cd36/ mice
(Fig. 6F). These findings provide direct functional support
for the suggestion that increased gallbladder contractility in
Cd36/ and DKO mice might contribute to the protection
observed against gallstone formation. We also examined
parameters of inflammation in the gallbladders of LD-fed
mice because prior work has suggested altered inflammasome induction in response to cholesterol-modulated pathways in atherosclerosis (33). These findings demonstrated
an inconsistent adaptive pattern of mRNAs encoding proinflammatory and antiinflammatory mediators (Fig. 6G), with
decreased expression of TNFa, but increased expression of
TLR2, TLR4, IL1b, IL18, and Nlrp3 in Cd36/ mice. Histologic examination of gallbladders from LD-fed WT and
Cd36/ mice (Fig. 6H) revealed mucosal hypertrophy and
increased submucosal thickening only in WT mice, with no
obvious inflammatory changes evident in gallbladders from
Cd36/ mice. Finally, we asked whether the changes observed above in gallbladder function were associated with
alterations in lipid accumulation. These findings revealed a
trend to reduced accumulation of all lipid classes analyzed,
with reduced free cholesterol reaching statistical significance (Fig. 6I). Taken together, the findings indicate that a
range of adaptive changes in gallbladder mucosal function
and lipid accumulation likely contribute to the protection
against gallstone formation.

TABLE 2. Biliary lipid secretion in LD-fed mice of the indicated genotype
Genotype

WT (12)
/
(7)
Cd36
L-Fabp/ (9)
DKO (4)

TC

PL
a

210.5 ± 6.9
a
175.1 ± 8.6
b
298.3 ± 11.9
221.8 ± 8.8ab

BA
a

646.7 ± 14.9
603.3 ± 24.1a
985.6 ± 39.9b
819.7 ± 31.9a

Flow rate
a

5103.8 ± 233.7
4827.9 ± 302.6a
6907.5 ± 426.3b
3900.1 ± 589.3a

91.6 ± 1.2
89.3 ± 1.7
115.9 ± 4.5
83.2 ± 0.7

Mice from four experimental groups (n per group) were fed a LD for 2 weeks. Bile samples were collected after
surgical laparotomy for 1 h. Biliary cholesterol (TC), phospholipids (PLs), and bile acids (BAs) were analyzed (Materials
and Methods). Biliary lipid secretion is expressed as nmol/min/kg bw. Flow rate is expressed as µl/min/kg bw. The
difference between values associated with different superscript letters for the parameters indicated in each vertical
column is statistically significant (P < 0.05).

absorption when those mice were fed the LD. These observations diminish the likelihood that genetically manipulated mice might be protected against gallstone
formation simply by virtue of decreased intestinal cholesterol absorption.
We considered an alternative hypothesis to account
for the protection against gallstones in Cd36/ mice,
namely, that compensatory adaptations in hepatic metabolic pathways might mitigate the impact of LD-induced
abnormalities. In considering this hypothesis, we were
guided by prior findings demonstrating that hepatic CD36
expression increases upon high-fat feeding (as in our
LD model; Fig. 5C) (14) and also findings in a line of
liver-specific Cd36 KO mice demonstrating protection
against high-fat diet-induced hepatic steatosis, along with
decreased hepatic fatty acid uptake (36). Other findings,
however, have challenged the conclusions that hepatic
fatty acid uptake is decreased in Cd36/ mice (31, 37). In
particular, those studies pointed to a role for CD36 in
regulating both de novo lipogenesis and also VLDL secretion as key considerations (31, 37). The observation
that hyperphagic ob/ob mice crossed into Cd36/ mice
manifested increased hepatic steatosis because of decreased VLDL secretion (37) might have special relevance to this discussion. This proposed function of CD36
in regulating hepatic VLDL secretion reminded us of
our previous findings that liver-specific Mttp deletion
(Mttp-LKO mice) reduced LD-induced gallstone formation because we showed that crossing Mttp-LKO mice into
L-Fabp/ mice conferred protection against LD-induced
gallstones (38). Accordingly, those findings in ob/ob mice
crossed into Cd36/ mice (37) reinforced the possibility that a hepatocyte-specific pathway of altered lipid
metabolism (either altered de novo lipogenesis and/or
decreased VLDL secretion) might attenuate gallstone susceptibility in Cd36-LKO mice. However, because this was
not the case, we conclude that hepatocyte-specific functions of CD36 cannot alone account for the gallstone protection phenotype observed in Cd36/ mice. We cannot
definitively explain the observation that CD36 mRNA
expression in whole liver extracts appeared to increase
after LD feeding (Fig. 5C), although we recognize that
other, nonhepatocyte populations (macrophages and
Kupffer cells) express CD36 (17), and it is plausible that
LD feeding induces adaptive increases in CD36 expression in these cell types. However, this possibility remains
to be tested experimentally.
CD36 deletion abrogates gallstone formation
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adaptive mechanisms that include alterations in biliary
cholesterol secretion and bile acid composition, as well as
increased gallbladder contractility. In addition, Cd36/
mice crossed into L-Fabp/ mice were also protected, reversing the gallstone susceptibility phenotype previously
observed in L-Fabp/ mice (12). However, and despite
evidence demonstrating adaptive alterations in cholesterol and bile acid metabolic pathways in both the intestine and liver of germline Cd36/ mice, we found that
neither intestine-specific nor liver-specific Cd36 deletion
alone was capable of replicating the protection phenotype. Several aspects of these conclusions merit additional
consideration.
Our initial hypothesis that Cd36/ mice might be protected against LD-induced gallstones was based on findings
that these mice exhibit decreased intestinal cholesterol
absorption and trafficking (15, 16). We reasoned that
decreased cholesterol absorption in Cd36/ mice might
prevent gallstone formation in a manner analogous to
ezetimibe treatment (34, 35). However, it seemed equally
plausible that Cd36/ mice might actually exhibit increased susceptibility to LD-induced gallstone formation,
based on other work showing that genetic strategies that
mitigate high-fat diet-induced hepatic steatosis in mice
(such as deletion of Elovl6 or of L-Fabp) demonstrated accelerated gallstone formation (12, 13). The current findings point to a gallstone-protection phenotype in LD-fed
Cd36/ mice with changes in both intestinal and hepatic
pathways contributing to complementary adaptations in
cholesterol and bile acid metabolism, but with no dominant protective mechanism.
Having demonstrated that germline Cd36/ mice were
protected against LD-induced gallstone formation, we
were initially surprised that intestine-specific Cd36 deletion failed to replicate a protection phenotype. As noted
above, this hypothesis was predicated in part on prior
findings that intestinal cholesterol absorption is decreased
in Cd36/ mice (15, 16). However, we recalled that the
alterations observed in intestinal cholesterol uptake
and processing in chow-fed Cd36/ mice are regionally
specific (proximal greater than distal), and it remains
to be determined whether net cholesterol absorption
and flux from the intestine is altered in Cd36/ mice
fed a cholic acid-supplemented LD. By way of comparison, we previously observed decreased intestinal cholesterol absorption in chow-fed L-Fabp/ mice (12), yet we
found no differences (from WT controls) in cholesterol

As a final consideration, we examined the possibility that
altered smooth muscle function and, in particular, altered
gallbladder motility might play a role in the protection observed. Our observations point to yet another function for
CD36, specifically in regulating gallbladder contractility.
Several studies have demonstrated that reduced gallbladder and small intestinal motility promotes gallstone formation (19, 32, 34). Our current observations of increased
gallbladder contractility along with the visual appearance of smaller gallbladders in Cd36/ mice might appear
somewhat unexpected, based on prior work demonstrating
reduced enteroendocrine cell production of CCK and
1698
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secretin in Cd36/ mice (20). Nevertheless, it is important to note that these contractility studies were conducted
in vitro, and we did not independently validate changes in
circulating CCK or secretin levels in Cd36/ mice fed a LD.
In addition, although those prior studies demonstrated
no change in gastric emptying in chow-fed Cd36/ mice
(20), we did not independently examine intestinal transit
or motility in LD-fed mice, as reported by others (34).
Accordingly, conclusions regarding alterations in intestinal motility and other details of gallbladder function
that may be regulated by CD36 remain to be examined.
However, we would predict that, because gallbladder CD36
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Fig. 3. Adaptive changes in hepatic and intestinal gene expression in LD-fed mice of the indicated genotypes. A, B: RNA was extracted
from liver or scraped proximal intestinal mucosa, and mRNA abundance was determined by Real-time quantitative PCR. A: Hepatic mRNA
expression. B: Proximal intestinal mRNA expression. C: NPC1L1 and SR-B1 protein expression in proximal intestinal mucosa. Thirty micrograms of protein was separated by SDS-PAGE gel, and the indicated proteins were detected by Western blot (upper). Band density was quantitated, and the data are presented as the mean ± SE (lower). D: Protein was extracted from terminal ileum and aliquots of total homogenate
(Fgf15) or purified apical membranes (Asbt) separated on SDS-PAGE gel, and the indicated protein was detected by Western blot. The relative abundance of Fgf15 and Asbt were quantitated by using a Kodak image system, and the data are presented as the mean ± SE. *Statistically
significant differences (P < 0.05).

mRNA was unaltered in either Cd36-IKO or Cd36-LKO
mice (Fig. 6C), it would be unlikely that a cross between the
liver- and intestine-specific Cd36 KO lines would yield

a gallstone protection phenotype. This prediction has
yet to be tested, but at least raises, in principle, the possibility (alluded to above) that alterations in yet other, cellspecific CD36-dependent pathways might be relevant to
gallstone pathogenesis.
CD36 deletion abrogates gallstone formation
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Fig. 4. Intestine-specific Cd36 deletion does not protect against LDinduced gallstone formation. Cd36-IKO mice and their littermate
flox/flox controls were fed a LD for 4 weeks. A: Visible gallstones were
observed in both genotypes (upper). Polarizing microscopy revealed
aggregated ChMCs in both genotypes (lower; 200×). Gallstone incidence (B), gallstone score (C) and gallbladder volume (D) was determined as described in Materials and Methods. E: Hepatic lipids were
extracted and quantitated enzymatically (Materials and Methods).
Hepatic lipid content is expressed as g/mg protein, except FFA,
which is expressed as nmol/mg protein. The data in C–E represent
the mean ± SE. n = 4–6 per group. BA, bile acid, CE, cholesteryl ester;
FC, free cholesterol; PL, phospholipid; TC, total cholesterol.

Fig. 5. Hepatocyte-specific Cd36 deletion does not protect against
LD-induced gallstone formation. Cd36-LKO mice were generated
as described (Materials and Methods). A: DNA was extracted from
hepatocytes (H) and the remnant, nonhepatocyte fraction of cells
(O) after liver perfusion, and the DNA was analyzed by agarose gel.
The hepatocyte fraction from Cd36- LKO mice shows Cre-mediated
recombination. B: Hepatocytes were prepared from chow-fed Cd36LKO mice and flox/flox controls, and extracts were subjected to
Western blotting for CD36. C: Whole liver extracts were prepared
from Cd36-LKO mice and flox/flox controls fed LD for 4 weeks and
Western-blotted for CD36. D: Visible gallstones were observed in
both Cd36-LKO and littermate control gallbladders (representative
gross appearances of gallbladder in upper). Polarizing microscopy
revealed aggregated ChMCs in both genotypes (lower; 200×). Gallstone incidence (E), gallstone score (F), and gallbladder volume
(G) were determined as described in Materials and Methods. H:
Hepatic lipids were extracted and quantitated enzymatically (Materials and Methods). Hepatic lipid content is expressed as g/mg
protein except FFA, which is expressed as nmol/mg protein. The
data in C–E represent the mean ± SE. n = 4–6 per group. BA, bile
acid, FC, free cholesterol; PL, phospholipid; TC, total cholesterol.
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